These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 15342382)

  • 1. Conditional deletion of Rb causes early stage prostate cancer.
    Maddison LA; Sutherland BW; Barrios RJ; Greenberg NM
    Cancer Res; 2004 Sep; 64(17):6018-25. PubMed ID: 15342382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer.
    Zhou Z; Flesken-Nikitin A; Corney DC; Wang W; Goodrich DW; Roy-Burman P; Nikitin AY
    Cancer Res; 2006 Aug; 66(16):7889-98. PubMed ID: 16912162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sex hormone-induced carcinogenesis in Rb-deficient prostate tissue.
    Wang Y; Hayward SW; Donjacour AA; Young P; Jacks T; Sage J; Dahiya R; Cardiff RD; Day ML; Cunha GR
    Cancer Res; 2000 Nov; 60(21):6008-17. PubMed ID: 11085521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conditional deletion of insulin-like growth factor-I receptor in prostate epithelium.
    Sutherland BW; Knoblaugh SE; Kaplan-Lefko PJ; Wang F; Holzenberger M; Greenberg NM
    Cancer Res; 2008 May; 68(9):3495-504. PubMed ID: 18451178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disruption of Rb/E2F pathway results in increased cyclooxygenase-2 expression and activity in prostate epithelial cells.
    Davis JN; McCabe MT; Hayward SW; Park JM; Day ML
    Cancer Res; 2005 May; 65(9):3633-42. PubMed ID: 15867358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Focal degeneration of basal cells and the resultant auto-immunoreactions: a novel mechanism for prostate tumor progression and invasion.
    Man YG; Gardner WA
    Med Hypotheses; 2008; 70(2):387-408. PubMed ID: 17658698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Function and therapeutic implication of C-CAM cell-adhesion molecule in prostate cancer.
    Lin SH; Pu YS
    Semin Oncol; 1999 Apr; 26(2):227-33. PubMed ID: 10597733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inactivation of Apc in the mouse prostate causes prostate carcinoma.
    Bruxvoort KJ; Charbonneau HM; Giambernardi TA; Goolsby JC; Qian CN; Zylstra CR; Robinson DR; Roy-Burman P; Shaw AK; Buckner-Berghuis BD; Sigler RE; Resau JH; Sullivan R; Bushman W; Williams BO
    Cancer Res; 2007 Mar; 67(6):2490-6. PubMed ID: 17363566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated E2F1 inhibits transcription of the androgen receptor in metastatic hormone-resistant prostate cancer.
    Davis JN; Wojno KJ; Daignault S; Hofer MD; Kuefer R; Rubin MA; Day ML
    Cancer Res; 2006 Dec; 66(24):11897-906. PubMed ID: 17178887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alterations of p53 are common in early stage prostate cancer.
    Downing SR; Russell PJ; Jackson P
    Can J Urol; 2003 Aug; 10(4):1924-33. PubMed ID: 14503938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumour suppressor genes in prostate cancer.
    MacGrogan D; Bookstein R
    Semin Cancer Biol; 1997 Feb; 8(1):11-9. PubMed ID: 9299577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interspecies comparison of prostate cancer gene-expression profiles reveals genes associated with aggressive tumors.
    Kela I; Harmelin A; Waks T; Orr-Urtreger A; Domany E; Eshhar Z
    Prostate; 2009 Jul; 69(10):1034-44. PubMed ID: 19343735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry.
    Sage J; Miller AL; Pérez-Mancera PA; Wysocki JM; Jacks T
    Nature; 2003 Jul; 424(6945):223-8. PubMed ID: 12853964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Earlier onset of melanotroph carcinogenesis in mice with inherited mutant paternal allele of the retinoblastoma gene.
    Nikitin AY; Riley DJ; Lee WH
    Cancer Res; 1997 Oct; 57(19):4274-8. PubMed ID: 9331088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate cancer associated with p53 and Rb deficiency arises from the stem/progenitor cell-enriched proximal region of prostatic ducts.
    Zhou Z; Flesken-Nikitin A; Nikitin AY
    Cancer Res; 2007 Jun; 67(12):5683-90. PubMed ID: 17553900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The type III transforming growth factor-beta receptor as a novel tumor suppressor gene in prostate cancer.
    Turley RS; Finger EC; Hempel N; How T; Fields TA; Blobe GC
    Cancer Res; 2007 Feb; 67(3):1090-8. PubMed ID: 17283142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survey of genetically engineered mouse models for prostate cancer: analyzing the molecular basis of prostate cancer development, progression, and metastasis.
    Kasper S
    J Cell Biochem; 2005 Feb; 94(2):279-97. PubMed ID: 15565647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model.
    Narayanan BA; Narayanan NK; Pittman B; Reddy BS
    Clin Cancer Res; 2004 Nov; 10(22):7727-37. PubMed ID: 15570007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autochthonous mouse models for prostate cancer: past, present and future.
    Huss WJ; Maddison LA; Greenberg NM
    Semin Cancer Biol; 2001 Jun; 11(3):245-60. PubMed ID: 11407949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incomplete inhibition of the Rb tumor suppressor pathway in the context of inactivated p53 is sufficient for pancreatic islet tumorigenesis.
    Casanovas O; Hager JH; Chun MG; Hanahan D
    Oncogene; 2005 Oct; 24(44):6597-604. PubMed ID: 16007165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.